PDF(Pubmed)
Abstract：
This study examined the effects of recombinant human brain natriuretic peptide (rhBNP) combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure (HF). This retrospective study included 90 patients with severe HF who were treated at our hospital between January 2019 and August 2021. Patients treated with tolvaptan tablets were assigned to the control group, and those treated with rhBNP combined with tolvaptan were assigned to the observation group. Efficacy, cardiac function, levels of inflammatory factors, renal function, 6 minutes walking test, Minnesota Living with Heart Failure Questionnaire score, and adverse reactions were assessed. The curative effect (97.78% vs 77.78%) and improvement in cardiac function were greater in the observation group than in the control group (P < .05). Decreased levels of inflammatory factors were seen in both groups after treatment, and the levels of tumor necrosis factor-α, interleukin-33, and intercellular adhesion factor-1 in the observation group were lower than those in the control group (P < .05). The 6 minutes walking test was higher and the Minnesota Living with Heart Failure Questionnaire score was lower in the observation group compared with the control group (P < .05). The incidence of adverse reactions such as dry mouth, nausea, polyuria, hypotension, and headache in the observation group was lower than that in the control group (P < .05). In conclusion, for patients with severe HF, rhBNP combined with tolvaptan can improve cardiac function, alleviate symptoms of dyspnea, protect renal function, and reduce serum inflammatory factor levels when compared with tolvaptan alone.
摘要：
本研究观察重组人脑利钠肽(rhBNP)联合托伐普坦对重症心力衰竭(HF)患者心肾功能及血清炎症因子的影响。这项回顾性研究包括2019年1月至2021年8月在我院接受治疗的90例严重HF患者。托伐普坦片治疗的患者被分配到对照组，将接受rhBNP联合托伐普坦治疗的患者分为观察组。功效,心功能,炎症因子水平，肾功能,6分钟步行测试，明尼苏达州心力衰竭患者生活问卷评分，并对不良反应进行评估。观察组的疗效（97.78％vs77.78％）和心功能改善均优于对照组（P<0.05）。两组患者治疗后炎症因子水平均下降,和肿瘤坏死因子-α的水平，观察组白细胞介素-33、细胞间黏附因子-1水平低于对照组(P<0.05)。与对照组相比，观察组6分钟步行试验得分较高，明尼苏达心力衰竭生活问卷得分较低（P<0.05）。口干等不良反应的发生率，恶心,多尿,低血压,观察组头痛发生率低于对照组(P<0.05)。总之,对于重度HF患者，rhBNP联合托伐普坦可改善心功能,缓解呼吸困难的症状，保护肾功能，与单独使用托伐普坦相比，降低血清炎症因子水平。
